| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Tyrosinase-IN-16 targets tyrosinase, the key enzyme in melanin biosynthesis. It is a potent tyrosinase inhibitor with a Ki of 470 nM. By inhibiting tyrosinase, the compound reduces melanin production. Tyrosinase-IN-16 is cytotoxic to B16F10 melanoma cells.
|
|---|---|
| ln Vitro |
Tyrosinase-IN-16 demonstrates potent in vitro tyrosinase inhibitory activity with a Ki of 470 nM. It is cytotoxic to B16F10 cells, with >90% inhibition at 20 µM. These in vitro findings confirm the compound's potent tyrosinase inhibition and its effects on melanoma cells.
|
| ln Vivo |
In vivo activity data for Tyrosinase-IN-16 are not extensively documented. Its potent tyrosinase inhibitory activity and cytotoxicity against B16F10 cells suggest potential in vivo efficacy for melanoma treatment or skin lightening. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for Tyrosinase-IN-16 involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically. Tyrosinase-IN-16 is incubated with the enzyme and substrate at various concentrations. The Ki value is determined by fitting the inhibition data.
|
| Cell Assay |
In vitro cellular assays for Tyrosinase-IN-16 typically use B16F10 melanoma cells. Cells are treated with the compound at various concentrations. Cell viability is measured using standard assays such as MTT or CellTiter-Glo. The compound's cytotoxicity is quantified as the percentage of inhibition at a given concentration.
|
| Animal Protocol |
In vivo animal experiments for Tyrosinase-IN-16 are not extensively documented. As a compound with cytotoxicity against melanoma cells, standard in vivo studies would involve mouse xenograft models of melanoma. Tumor-bearing mice would be administered Tyrosinase-IN-16 via oral or parenteral routes. Tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tyrosinase-IN-16 are not extensively documented. As a small molecule with a triazole-thione scaffold, the compound is expected to have reasonable bioavailability. Its chemical structure may influence its absorption, distribution, metabolism, and excretion. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Tyrosinase-IN-16 are not extensively available. As a research compound, it has not undergone extensive toxicological evaluation. Its cytotoxicity against B16F10 cells suggests potential toxicity concerns. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
Tyrosinase-IN-16 (compound 19a) is a synthetic tyrosinase inhibitor with a 1,2,4-triazole-3-thione scaffold and a Ki of 470 nM. It is cytotoxic to B16F10 cells with >90% inhibition at 20 µM. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C8H6BRN3S
|
|---|---|
| Molecular Weight |
256.12234
|
| Exact Mass |
254.947
|
| CAS # |
126651-85-2
|
| PubChem CID |
676286
|
| Appearance |
White to off-white solid powder
|
| Density |
1.83g/cm3
|
| Boiling Point |
326.6ºC at 760 mmHg
|
| Flash Point |
151.3ºC
|
| Vapour Pressure |
0.000214mmHg at 25°C
|
| Index of Refraction |
1.775
|
| LogP |
2.896
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
254
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC(=C1)Br)C2=NC(=S)NN2
|
| InChi Key |
ALETZOQAGIEADS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H6BrN3S/c9-6-3-1-2-5(4-6)7-10-8(13)12-11-7/h1-4H,(H2,10,11,12,13)
|
| Chemical Name |
5-(3-bromophenyl)-1,2-dihydro-1,2,4-triazole-3-thione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9044 mL | 19.5221 mL | 39.0442 mL | |
| 5 mM | 0.7809 mL | 3.9044 mL | 7.8088 mL | |
| 10 mM | 0.3904 mL | 1.9522 mL | 3.9044 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
